Literature DB >> 18068483

The filaggrin story: novel insights into skin-barrier function and disease.

John A McGrath1, Jouni Uitto.   

Abstract

Recent reports have uncovered the key role of the protein filaggrin in maintaining an effective skin barrier against the external environment. Loss-of-function mutations in the profilaggrin gene (FLG) are common and are present in up to 10% of the population. These mutations are the cause of the semi-dominant skin-scaling disorder ichthyosis vulgaris and are a major risk factor for the development of atopic dermatitis. The discovery of these mutations also provides new data concerning the genetics of atopic asthma as well as intriguing insight into disease mechanisms of systemic allergies involving antigen exposure in skin with defective barrier function. Collectively, these novel findings have significant implications for the classification and future clinical management of patients with atopic and allergic diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18068483     DOI: 10.1016/j.molmed.2007.10.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  53 in total

1.  Gelatin-based anionic hydrogel as biocompatible substrate for human keratinocyte growth.

Authors:  Filippo Renò; Manuela Rizzi; Mario Cannas
Journal:  J Mater Sci Mater Med       Date:  2011-12-13       Impact factor: 3.896

Review 2.  Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases.

Authors:  Akiharu Kubo; Keisuke Nagao; Masayuki Amagai
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

Review 3.  Eczema in early life: genetics, the skin barrier, and lessons learned from birth cohort studies.

Authors:  Jocelyn M Biagini Myers; Gurjit K Khurana Hershey
Journal:  J Pediatr       Date:  2010-08-24       Impact factor: 4.406

4.  Overexpression of constitutively active BMP-receptor-IB in mouse skin causes an ichthyosis-vulgaris-like disease.

Authors:  Xueyan Yu; Ramón A Espinoza-Lewis; Cheng Sun; Lisong Lin; Fenglei He; Wei Xiong; Jing Yang; Alun Wang; Yiping Chen
Journal:  Cell Tissue Res       Date:  2010-11-16       Impact factor: 5.249

Review 5.  Animal models of skin disease for drug discovery.

Authors:  Pinar Avci; Magesh Sadasivam; Asheesh Gupta; Wanessa Cma De Melo; Ying-Ying Huang; Rui Yin; Rakkiyappan Chandran; Raj Kumar; Ayodeji Otufowora; Theodore Nyame; Michael R Hamblin
Journal:  Expert Opin Drug Discov       Date:  2013-01-08       Impact factor: 6.098

6.  Systems-level analysis of proteolytic events in increased vascular permeability and complement activation in skin inflammation.

Authors:  Ulrich auf dem Keller; Anna Prudova; Ulrich Eckhard; Barbara Fingleton; Christopher M Overall
Journal:  Sci Signal       Date:  2013-01-15       Impact factor: 8.192

7.  External antigen uptake by Langerhans cells with reorganization of epidermal tight junction barriers.

Authors:  Akiharu Kubo; Keisuke Nagao; Mariko Yokouchi; Hiroyuki Sasaki; Masayuki Amagai
Journal:  J Exp Med       Date:  2009-12-07       Impact factor: 14.307

Review 8.  Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis.

Authors:  Sang Eun Lee; Se Kyoo Jeong; Seung Hun Lee
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

9.  Neutral cysteine protease bleomycin hydrolase is essential for the breakdown of deiminated filaggrin into amino acids.

Authors:  Yayoi Kamata; Aya Taniguchi; Mami Yamamoto; Junko Nomura; Kazuhiko Ishihara; Hidenari Takahara; Toshihiko Hibino; Atsushi Takeda
Journal:  J Biol Chem       Date:  2009-03-13       Impact factor: 5.157

10.  Carrier status for the common R501X and 2282del4 filaggrin mutations is not associated with hearing phenotypes in 5,377 children from the ALSPAC cohort.

Authors:  Santiago Rodriguez; Amanda J Hall; Raquel Granell; W H Irwin McLean; Alan D Irvine; Colin N A Palmer; George Davey Smith; John Henderson; Ian N M Day
Journal:  PLoS One       Date:  2009-06-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.